- Home
- COCP vs NRXS Comparison
COCP vs NRXS Comparison
Compare COCP & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- NRXS
- Stock Information
- Founded
- COCP N/A
- NRXS 2011
- Country
- COCP United States
- NRXS United States
- Employees
- COCP N/A
- NRXS N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- COCP Health Care
- NRXS
- Exchange
- COCP Nasdaq
- NRXS Nasdaq
- Market Cap
- COCP 18.2M
- NRXS 20.8M
- IPO Year
- COCP N/A
- NRXS 2023
- Fundamental
- Price
- COCP $2.04
- NRXS $2.95
- Analyst Decision
- COCP Strong Buy
- NRXS
- Analyst Count
- COCP 1
- NRXS 0
- Target Price
- COCP $7.00
- NRXS N/A
- AVG Volume (30 Days)
- COCP 18.6K
- NRXS 6.5K
- Earning Date
- COCP 11-11-2024
- NRXS 11-18-2024
- Dividend Yield
- COCP N/A
- NRXS N/A
- EPS Growth
- COCP N/A
- NRXS N/A
- EPS
- COCP N/A
- NRXS N/A
- Revenue
- COCP N/A
- NRXS $2,267,053.00
- Revenue This Year
- COCP N/A
- NRXS $383.16
- Revenue Next Year
- COCP N/A
- NRXS N/A
- P/E Ratio
- COCP N/A
- NRXS N/A
- Revenue Growth
- COCP N/A
- NRXS N/A
- 52 Week Low
- COCP $1.33
- NRXS $1.80
- 52 Week High
- COCP $3.10
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- COCP 61.73
- NRXS 48.76
- Support Level
- COCP $1.66
- NRXS $2.62
- Resistance Level
- COCP $1.87
- NRXS $2.97
- Average True Range (ATR)
- COCP 0.15
- NRXS 0.14
- MACD
- COCP 0.04
- NRXS -0.00
- Stochastic Oscillator
- COCP 48.10
- NRXS 59.71
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).